|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| 12345678910111213...1819» |
- | bleselumab (ASKP1240) / Astellas, Kyowa Kirin
Phase classification: A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Jan 9, 2024
P2, N=60, Completed, Sponsor: Astellas Pharma Global Development, Inc.
Phase classification: P2a --> P2
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Potential Research Study Participant Registry (clinicaltrials.gov) - Feb 16, 2019
P=N/A, N=265, Completed, Sponsor: University of California, Davis
Phase classification: P2a --> P2 Recruiting --> Completed | N=200 --> 265 | Trial completion date: Jan 2025 --> Sep 2018 | Trial primary completion date: Jan 2025 --> Sep 2018
- || Sorilux (calcipotriene foam) / Mayne Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis (clinicaltrials.gov) - Jan 22, 2019
P1, N=36, Completed, Sponsor: Mayne Pharma International Pty Ltd
Recruiting --> Completed | N=200 --> 265 | Trial completion date: Jan 2025 --> Sep 2018 | Trial primary completion date: Jan 2025 --> Sep 2018 Recruiting --> Completed | N=75 --> 36 | Trial completion date: Apr 2019 --> Aug 2018 | Trial primary completion date: Apr 2019 --> Aug 2018
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date, IO biomarker: Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques (clinicaltrials.gov) - Jan 5, 2019
P2, N=7, Completed, Sponsor: Tissa Hata, MD
Recruiting --> Completed | N=75 --> 36 | Trial completion date: Apr 2019 --> Aug 2018 | Trial primary completion date: Apr 2019 --> Aug 2018 Recruiting --> Completed | N=10 --> 7 | Trial completion date: Jul 2017 --> Feb 2018 | Trial primary completion date: Jul 2017 --> Mar 2017
- | Trial termination: Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis (clinicaltrials.gov) - Dec 4, 2018
P4, N=30, Terminated, Sponsor: University of California, San Francisco
Recruiting --> Completed | N=10 --> 7 | Trial completion date: Jul 2017 --> Feb 2018 | Trial primary completion date: Jul 2017 --> Mar 2017 Completed --> Terminated
- | Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Trial completion date, Trial primary completion date: Initial Treatment With Golimumab in Early PsA (clinicaltrials.gov) - Nov 26, 2018
P3, N=51, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Completed --> Terminated Recruiting --> Completed | Trial completion date: Dec 2016 --> Nov 2018 | Trial primary completion date: Jun 2016 --> Nov 2018
- | Enbrel (etanercept) / Pfizer, Amgen, Yisaipu (etanercept biosimilar) / Cipla, 3SBio, Abbott
Trial completion, Trial primary completion date: Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate (clinicaltrials.gov) - Aug 17, 2018
P4, N=466, Completed, Sponsor: Zhejiang University
Recruiting --> Completed | Trial completion date: Dec 2016 --> Nov 2018 | Trial primary completion date: Jun 2016 --> Nov 2018 Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Aug 2018
- | Trial completion, Phase classification, Trial completion date: Natural Gels for Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jul 23, 2018
P2/3, N=45, Completed, Sponsor: Secret of Youth
Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Aug 2018 Recruiting --> Completed | Phase classification: P1/2 --> P2/3 | Trial completion date: Dec 2016 --> Sep 2017
- | Trial completion: Vascular Effects of Achieving Minimal Disease Activity in Psoriatic Arthritis - a 2 Year Prospective Cohort Study (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=113, Completed, Sponsor: Chinese University of Hong Kong
Recruiting --> Completed | Phase classification: P1/2 --> P2/3 | Trial completion date: Dec 2016 --> Sep 2017 Active, not recruiting --> Completed
- | triamcinolone acetonide topical / Generic mfg.
Enrollment change, Trial withdrawal: DIPSO: Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis (clinicaltrials.gov) - Jul 19, 2018
P4, N=0, Withdrawn, Sponsor: University of Zurich
Active, not recruiting --> Completed N=88 --> 0 | Suspended --> Withdrawn
- | Cosentyx (secukinumab) / Novartis
Trial completion: FUTURE 3: 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis (clinicaltrials.gov) - Jul 13, 2018
P3, N=414, Completed, Sponsor: Novartis Pharmaceuticals
N=88 --> 0 | Suspended --> Withdrawn Active, not recruiting --> Completed
- ||| Stelara (ustekinumab) / J&J
Trial completion, Reimbursement, Trial completion date, Trial primary completion date, Claims database: Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database (clinicaltrials.gov) - Jun 15, 2018
P=N/A, N=2000, Completed, Sponsor: Janssen Biotech, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Sep 2017 | Trial primary completion date: Apr 2018 --> Sep 2017
- | Humira (adalimumab) / AbbVie
Trial completion: Vascular Inflammation in Psoriasis Trial (The VIP Trial) (clinicaltrials.gov) - Jun 3, 2018
P4, N=97, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Sep 2017 | Trial primary completion date: Apr 2018 --> Sep 2017 Active, not recruiting --> Completed
- | tacrolimus topical / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Tacrolimus Ointment Interest (PROTOPIC (clinicaltrials.gov) - Jun 1, 2018
P3, N=120, Completed, Sponsor: University Hospital, Rouen
Active, not recruiting --> Completed Recruiting --> Completed | N=240 --> 120 | Trial completion date: Jun 2018 --> Oct 2017
- | Phase classification, Enrollment change: Genetic Analysis of Psoriasis and Psoriatic Arthritis (clinicaltrials.gov) - Apr 6, 2018
P, N=2653, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=240 --> 120 | Trial completion date: Jun 2018 --> Oct 2017 Phase classification: P=N/A --> P | N=5000 --> 2653
- || Stelara (ustekinumab) / J&J
Phase classification, Reimbursement, Claims database: Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database (clinicaltrials.gov) - Mar 31, 2018
P, N=2000, Active, not recruiting, Sponsor: Janssen Biotech, Inc.
Phase classification: P=N/A --> P | N=5000 --> 2653 Phase classification: P=N/A --> P
- | Orencia (abatacept) / BMS, Stelara (ustekinumab) / J&J
Trial completion: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Mar 21, 2018
P2, N=108, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P=N/A --> P Active, not recruiting --> Completed
- ||||| Cosentyx (secukinumab) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date: FUTURE 3: 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis (clinicaltrials.gov) - Mar 5, 2018
P3, N=415, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Jan 2018 --> Mar 2018 | Initiation date: Apr 2014 --> Feb 2010 | Trial primary completion date: Jan 2018 --> Mar 2018
- |||| calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects (clinicaltrials.gov) - Mar 1, 2018
P2, N=102, Completed, Sponsor: LEO Pharma
Trial completion date: Jan 2018 --> Mar 2018 | Initiation date: Apr 2014 --> Feb 2010 | Trial primary completion date: Jan 2018 --> Mar 2018 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2018 | Trial completion date: Dec 2017 --> Feb 2018
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis (clinicaltrials.gov) - Feb 28, 2018
P3, N=675, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2018 | Trial completion date: Dec 2017 --> Feb 2018 Active, not recruiting --> Completed | Initiation date: Sep 2012 --> Aug 2008 | Trial completion date: May 2017 --> May 2017 | Trial primary completion date: May 2017 --> May 2017
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab (clinicaltrials.gov) - Nov 17, 2017
P3, N=1150, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Initiation date: Sep 2012 --> Aug 2008 | Trial completion date: May 2017 --> May 2017 | Trial primary completion date: May 2017 --> May 2017 Active, not recruiting --> Completed
- | rose bengal disodium (PH-10) / Provectus
Trial completion: A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 (clinicaltrials.gov) - Nov 13, 2017
P2, N=30, Completed, Sponsor: Provectus Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Betnovate (betamethasone valerate) / GSK
Enrollment change: Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 (clinicaltrials.gov) - Nov 13, 2017
P1, N=10, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=15 --> 10
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Oct 19, 2017
P=N/A, N=96, Completed, Sponsor: AbbVie
N=15 --> 10 Active, not recruiting --> Completed | N=140 --> 96
- | Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Trial completion, HEOR: Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation (clinicaltrials.gov) - Oct 13, 2017
P=N/A, N=26, Completed, Sponsor: University Hospitals Cleveland Medical Center
Active, not recruiting --> Completed | N=140 --> 96 Active, not recruiting --> Completed
- ||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis (clinicaltrials.gov) - Oct 5, 2017
P3, N=182, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: The NOR-SWITCH Study (clinicaltrials.gov) - Sep 25, 2017
P4, N=482, Completed, Sponsor: Diakonhjemmet Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Review, Trial primary completion date: Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis (clinicaltrials.gov) - Sep 6, 2017
P=N/A, N=370, Completed, Sponsor: Janssen Biotech, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion, IO biomarker: Mechanism of Action Study for Psoriasis (clinicaltrials.gov) - Aug 31, 2017
P4, N=33, Completed, Sponsor: Tufts Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016 Active, not recruiting --> Completed
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab (clinicaltrials.gov) - Aug 17, 2017
P3, N=237, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change, HEOR: Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis (clinicaltrials.gov) - Aug 11, 2017
P=N/A, N=1, Completed, Sponsor: Jochen Schmitt.
Active, not recruiting --> Completed N=1000 --> 1
- | Trial suspension, Trial primary completion date: Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease (clinicaltrials.gov) - Aug 4, 2017
P=N/A, N=200, Suspended, Sponsor: Gloucestershire Hospitals NHS Foundation Trust
N=1000 --> 1 Recruiting --> Suspended | Trial primary completion date: Aug 2016 --> Aug 2018
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Observational data: SPACTIVE: Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=183, Completed, Sponsor: AbbVie
Recruiting --> Suspended | Trial primary completion date: Aug 2016 --> Aug 2018 Active, not recruiting --> Completed
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial primary completion date: VIP-Et: Vascular Inflammation in Psoriasis - Extension Study (clinicaltrials.gov) - Jun 16, 2017
P4, N=81, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2018 --> Aug 2016
- || Sorilux (calcipotriene foam) / Mayne Pharma
Phase classification, Enrollment change: Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis (clinicaltrials.gov) - May 19, 2017
P1, N=75, Recruiting, Sponsor: Mayne Pharma International Pty Ltd
Active, not recruiting --> Completed | Trial primary completion date: Jul 2018 --> Aug 2016 Phase classification: P3 --> P1 | N=180 --> 75
- Sorilux (calcipotriene foam) / Mayne Pharma
Trial primary completion date: Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis (clinicaltrials.gov) - May 16, 2017
P1, N=30, Recruiting, Sponsor: Mayne Pharma International Pty Ltd
Phase classification: P3 --> P1 | N=180 --> 75 Trial primary completion date: Mar 2017 --> Jun 2017
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: TRANSFIGURE: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (clinicaltrials.gov) - May 9, 2017
P3, N=198, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2017 --> Jun 2017 Active, not recruiting --> Completed
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion: Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP) (clinicaltrials.gov) - Apr 28, 2017
P2, N=118, Completed, Sponsor: University College Dublin
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis (clinicaltrials.gov) - Apr 25, 2017
P2, N=13, Terminated, Sponsor: University of Medicine and Dentistry of New Jersey
Active, not recruiting --> Completed Completed --> Terminated; Low enrollment
- ||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: A Study of Golimumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Apr 21, 2017
P3, N=480, Completed, Sponsor: Janssen Research & Development, LLC
Completed --> Terminated; Low enrollment Active, not recruiting --> Completed
- Enrollment change: PRC-05-2011: Psoriatic Arthritis Treat to Target vs. Usual Care (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=0, Withdrawn, Sponsor: Pope Research Corporation
Active, not recruiting --> Completed N=230 --> 0
- | Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: Safety and Efficacy of Etanercept in Patients With Psoriasis (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=80, Active, not recruiting, Sponsor: Chengdu PLA General Hospital
N=230 --> 0 Trial primary completion date: Dec 2016 --> Dec 2022
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis (clinicaltrials.gov) - Mar 31, 2017
P3, N=182, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2016 --> Dec 2022 Trial primary completion date: Dec 2017 --> Dec 2011
- | Phase classification: Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=21, Completed, Sponsor: Tufts Medical Center
Trial primary completion date: Dec 2017 --> Dec 2011 Phase classification: P4 --> P=N/A
- | Trial completion, Enrollment change, Trial primary completion date: Neurobiology of the Scalp in Seborrheic Dermatitis (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=32, Completed, Sponsor: Boston University
Phase classification: P4 --> P=N/A Recruiting --> Completed | N=24 --> 32 | Trial primary completion date: Aug 2015 --> May 2014
- | Trial completion, Enrollment change, HEOR: Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=116, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=24 --> 32 | Trial primary completion date: Aug 2015 --> May 2014 Active, not recruiting --> Completed | N=150 --> 116
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial primary completion date, Real-world evidence, Real-world: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (clinicaltrials.gov) - Mar 21, 2017
P3, N=46, Completed, Sponsor: AbbVie
Active, not recruiting --> Completed | N=150 --> 116 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Mar 2017
- | Trial completion, Enrollment change: Prevalence of Sleep Disturbances in Psoriasis (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=64, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Mar 2017 Active, not recruiting --> Completed | N=80 --> 64
- | entecavir / Generic mfg.
Enrollment change: Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα (clinicaltrials.gov) - Mar 6, 2017
P3, N=43, Terminated, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed | N=80 --> 64 N=128 --> 43
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Phase classification, Review: Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=370, Active, not recruiting, Sponsor: Janssen Biotech, Inc.
N=128 --> 43 Phase classification: P4 --> P=N/A